Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03874832 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects
A Phase 1 study of Migraine and Migraine With Aura, sponsored by Satsuma Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 46
- Enrollment target
- 1
- Study location
NCT03874832 is a Phase 1 study of Migraine and Migraine With Aura that has completed, run by Satsuma Pharmaceuticals. The registered enrollment target is 46 participants, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (87% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03874832, a Phase 1 study of Migraine and Migraine With Aura, has completed, sponsored by Satsuma Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 46 participants
- Enrollment target
- 1
- Study location
Study Summary
Single-center, single-dose, open-label, 2-part, 3-period crossover (in each part), pharmacokinetic and safety study.
Conditions Studied
Interventions
- DRUG Dihydroergotamine
Study Locations (1)
Florida
- Quotient Sciences Miami Inc. - Miami
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2018-09-11 |
| Est. Completion | 2018-11-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03874832
The ClinicalTrials.gov registry entry for NCT03874832 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 358-participant average among 102 other Migraine trials with a reported enrollment target (87% lower). The listed sponsor is Satsuma Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Migraine appearing as the primary indexed condition, and to 1 intervention - of which Dihydroergotamine is the first listed.
NCT03874832 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT03874832 about?
NCT03874832 is a clinical study titled "A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects". Single-center, single-dose, open-label, 2-part, 3-period crossover (in each part), pharmacokinetic and safety study.
What is the current status of trial NCT03874832?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 46 participants. The study started on 2018-09-11. Estimated completion is 2018-11-07.
What conditions does trial NCT03874832 study?
This clinical trial studies the following conditions: Migraine, Migraine With Aura, Migraine Without Aura.
What interventions are being tested in trial NCT03874832?
The interventions under investigation include: Dihydroergotamine (DRUG).
Who is sponsoring clinical trial NCT03874832?
This trial is sponsored by Satsuma Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03874832 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Migraine
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants
COMPLETED · Phase 1
-
Safety and Pharmacokinetics (PK) Study of Single Ascending Doses of CVT-427 (Zolmitriptan Inhalation Powder) In Healthy Adults
COMPLETED · Phase 1
-
Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine
COMPLETED · Phase 1
-
A Study Investigating the Movement of Lu AG09222 Into, Through, and Out of the Body of Healthy Caucasian, Chinese, and Japanese Participants
COMPLETED · Phase 1
-
A Study of the Pulmonary Safety and Pharmacokinetics of Zolmitriptan Inhalation Powder
COMPLETED · Phase 1
-
Migraine Manager (R01)
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.